Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Items 301–400 of 860
Rapamycin Responds to Alzheimer’s Disease: A Potential Translational Therapy
Hou, S.-J., Zhang, S., Li, Y., & Xu, S.-Y. (2023) · Clinical Interventions in Aging · doi:10.2147/cia.s429440 · Cited by 61
5-HT6 Receptor: A New Player Controlling the Development of Neural Circuits
Dayer, A. G., Jacobshagen, M., Chaumont-Dubel, S., & Marin, P. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn500326z · Cited by 58
Magdalon, J., Sánchez-Sánchez, S. M., Griesi‐Oliveira, K., & Sertie, A. L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030659 · Cited by 60
“Finally, and perhaps most importantly, a direct role for overactivated mTORC1 signaling in ASD core symptoms is supported by multiple evidence in mouse models of TSC [77,87,88], PTEN-ASD [100], FXS [160,166] and eIF4E-NS-ASD [49,50], showing that pharmacological or genetic inhibition of mTORC1 cascade both upstream an…”
BackgroundTuberous Sclerosis: A New Frontier in Targeted Treatment of Autism
Davis, P. E., Peters, J. M., Krueger, D. A., & Şahin, M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0359-5 · Cited by 62
Signaling mechanisms regulating synapse formation and function in mental retardation
Boda, B., Dubos, A., & Muller, D. (2010) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2010.03.012 · Cited by 57
“mTOR signaling is also regulated by several other pathways: it is inhibited by the gene products implicated in tuberous sclerosis complex (TSC), a disease characterized by multiple benign tumors, epilepsy and mental retardation [51]; it is activated by Ras-Pi3K signaling [2], a pathway regulated by SynGAP and PTEN, tw…”
Cognitive deficits in Rett syndrome: What we know and what we need to know to treat them
Berger-Sweeney, J. E. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.05.006 · Cited by 64
“BDNF can also stimulate local synaptic synthesis of mRNA and is important for long term potentiation (LTP), which may underlie the encoding of memories (Johnston, Alemi, & Harum, 2003a).”
BackgroundInfluentialKotajima‐Murakami, H., Kobayashi, T., Kashii, H., Sato, A., Hagino, Y., Tanaka, M., Nishito, Y., Takamatsu, Y., Uchino, S., & Ikeda, K. (2019) · Molecular Brain · doi:10.1186/s13041-018-0423-2 · Cited by 59
Chévere-Torres, I., Maki, J. M., Santini, E., & Klann, E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.018 · Cited by 65
Communication, interventions, and scientific advances in autism: A commentary
Llaneza, D. C., DeLuke, S. V., Batista, M., Crawley, J. N., Christodulu, K. V., & Frye, C. A. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.01.003 · Cited by 75
“In a mousemodel, heterozygotes for the tuberous sclerosis gene Tsc2, display deficits in learning and memory [128].”
BackgroundHumphrey, A., MacLean, C., Ploubidis, G. B., Granader, Y., Clifford, M., Haslop, M., Neville, B. G. R., Yates, J. R. W., Bolton, P., & the Tuberous Sclerosis 2000 Study Group (2014) · Epilepsia · doi:10.1111/epi.12484 · Cited by 56
Rapamycin Protects Sepsis-Induced Cognitive Impairment in Mouse Hippocampus by Enhancing Autophagy
Liu, W., Guo, J., Mu, J., Tian, L., & Zhou, D. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0449-x · Cited by 56
WONOEP appraisal: Biomarkers of epilepsy‐associated comorbidities
Ravizza, T., Onat, F., Brooks‐Kayal, A. R., Depaulis, A., Galanopoulou, A. S., Mazarati, A. M., Numis, A. L., Sankar, R., & Friedman, A. (2016) · Epilepsia · doi:10.1111/epi.13652 · Cited by 57
“models of epilepsy is associated with cognitive and behavioral deficits, which are reversed following treatment with the mTOR inhibitor rapamycin.(21,22) This suggests that aberrant mTORC1 activation may be a candidate mechanism associated with the memory deficits seen in acquired or certain genetic forms of epilepsie…”
BackgroundWong, M. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.10.002 · Cited by 56
“In another mouse model of TSC, rapamycin can also reverse learning deficits (Ehninger et al., 2008).”
BackgroundIs mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero, R., Coniglio, A., Garaci, F., & Curatolo, P. (2013) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/1824-7288-39-57 · Cited by 55
“Evidence on animal models showed that mTOR signalling plays a crucial role in different social behaviours as well as in learning deficit [20], and a brief treatment with rapamycin rescued not only synaptic plasticity but also behavioral deficits [21].”
BackgroundMalik, R., Pai, E. L.-L., Rubin, A. N., Stafford, A. M., Angara, K., Minasi, P., Rubenstein, J. L. R., Sohal, V. S., & Vogt, D. L. (2019) · Nature Communications · doi:10.1038/s41467-019-12962-4 · Cited by 58
Spatiotemporally resolved protein synthesis as a molecular framework for memory consolidation
Shrestha, P., & Klann, E. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.01.004 · Cited by 54
Current perspectives in autism spectrum disorder: from genes to therapy
Chahrour, M., O'Roak, B. J., Santini, E., Samaco, R. C., Kleiman, R. J., & Manzini, M. C. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2335-16.2016 · Cited by 54
“Finally, mice with genetic deletion of Tsc1, Tsc2, or Pten showed a normalization of the ASD-like behaviors after treatment with rapamycin (Ehninger et al., 2008; Meikle et al., 2008; Zhou et al., 2009; Tsai et al., 2012), a potent inhibitor of mTORC1, the macromolecular complex central to the…”
BackgroundEmerging Pharmacotherapies for Neurodevelopmental Disorders
Wetmore, D. Z., & Garner, C. C. (2010) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181ee3833 · Cited by 63
Yuan, E. D., Tsai, P. T., Greene-Colozzi, E. A., Şahin, M., Kwiatkowski, D. J., & Malinowska, I. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds262 · Cited by 55
Self-citationJahrling, J., & Laberge, R.-M. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150610125856 · Cited by 53
“One study investigated transgenic mice modelling tuberous sclerosis and found that the animals exhibited both overactive mTORC1 and memory impairment which were subsequently normalized by treatment with rapamycin [46].”
BackgroundFu, J., Wang, H., Gao, J., Yu, M., Wang, R., Yang, Z. R., & Zhang, T. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9687-7 · Cited by 54
Şahin, M., Henske, E. P., Manning, B. D., Ess, K. C., Bissler, J. J., Klann, E., Kwiatkowski, D. J., Roberds, S. L., Silva, A. J., Hillaire‐Clarke, C. S., et al. (2016) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2016.03.015 · Cited by 63
Self-citationMasini, D., Bonito-Oliva, A., Bertho, M., & Fisone, G. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00208 · Cited by 51
“Notably, the cognitive impairment observed in animal models of tuberous sclerosis and Down syndrome is counteracted by rapamycin, a selective inhibitor of mTORC1 (13, 14, 18).”
BackgroundLeveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders
Searles, V. B., Wang, B., & State, M. W. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0768-y · Cited by 56
Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges
Moavero, R., Cerminara, C., & Curatolo, P. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1128-8 · Cited by 52
“Rapamycin makes the dysregulated mTOR pathway return to normal in cells that lack TSC1 or TSC2, and recently proved its efficacy in preventing epilepsy in mouse models of TSC [94–96].”
BackgroundmTOR signaling in neural stem cells: from basic biology to disease
Magri, L., & Galli, R. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1196-x · Cited by 54
Role of mTOR inhibitors in epilepsy treatment
Sadowski, K., Kotulska, K., & Jóźwiak, S. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.12.017 · Cited by 54
Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
Magri, L., Cominelli, M., Cambiaghi, M., Cursi, M., Leocani, L., Minicucci, F., Poliani, P. L., & Galli, R. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.012096 · Cited by 51
“…conditional knockout murine models have been generated, by causing loss of either Tsc1 or Tsc2 in differentiating or differentiated neuronal cells (Tsc1c/c/Syn-Cre+ and Tsc1c/c/CaMKII-Cre+ mice) (Meikle et al., 2007; Ehninger et al., 2008) or in differentiated astrocytes [Tsc1c/c/hGFAP2.”
Advances in the treatment of tuberous sclerosis complex
Leclezio, L., & de Vries, P. J. (2015) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000136 · Cited by 54
Yalon, M., Ben‐Sira, L., Constantini, S., & Toren, A. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1222-y · Cited by 50
“Furthermore, rapamycin and its analogs CCI-779 have successfully treated TSC-related kidney, subcutaneous, and pituitary tumors, as well as reducing seizures and cognitive defects in relevant rodent disease models [6, 7].”
BackgroundBasu, T., O’Riordan, K. J., Schoenike, B. A., Khan, N., Wallace, E. P., Rodriguez, G., Maganti, R. K., & Roopra, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-41744-7 · Cited by 51
The autism-associated protein CHD8 is required for cerebellar development and motor function
Kawamura, A., Katayama, Y., Kakegawa, W., Ino, D., Nishiyama, M., Yuzaki, M., & Nakayama, K. I. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108932 · Cited by 59
Mechanisms Underlying Circuit Dysfunction in Neurodevelopmental Disorders
Exposito-Alonso, D., & Rico, B. (2022) · Annual Review of Genetics · doi:10.1146/annurev-genet-072820-023642 · Cited by 49
Ehninger, D., & Silva, A. J. (2010) · Behavior Genetics · doi:10.1007/s10519-010-9398-1 · Cited by 51
“%) and disinhibited mTOR signaling in the hippocampus (Ehninger et al. 2008).”
BackgroundResultSelf-citationMetabotropic Glutamate Receptors in Central Nervous System Diseases
V. Golubeva, A., D. Moloney, R., M. O';Connor, R., G. Dinan, T., & F. Cryan, J. (2016) · Current Drug Targets · doi:10.2174/1389450116666150316224011 · Cited by 47
Kelly, E., Schaeffer, S. M., Dhamne, S. C., Lipton, J. O., Lindemann, L., Honer, M., Jaeschke, G., Super, C. E., Lammers, S. H. T., Modi, M. E., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.295 · Cited by 52
Self-citationMutant Mouse Models of Autism Spectrum Disorders
Provenzano, G., Zunino, G., Genovesi, S., Sgadó, P., & Bozzi, Y. (2012) · Disease Markers · doi:10.1155/2012/916082 · Cited by 59
The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer's disease
Gourmaud, S., Stewart, D. A., Irwin, D. J., Roberts, N., Barbour, A. J., Eberwine, G., O’Brien, W. T., Vassar, R. J., Talos, D. M., & Jensen, F. E. (2021) · Brain · doi:10.1093/brain/awab268 · Cited by 52
Advances in the management of subependymal giant cell astrocytoma
Beaumont, T., Limbrick, D. D., & Smyth, M. D. (2012) · Child s Nervous System · doi:10.1007/s00381-012-1785-x · Cited by 48
“The above observations in humans are further supported by animal models of TSC, where rapamycin treatment can prevent the development of seizures and reverse learning defects [36, 37].”
ResultMercer, A. A., Palarz, K. J., Tabatadze, N., Woolley, C. S., & Raman, I. M. (2016) · eLife · doi:10.7554/elife.07596 · Cited by 49
“Tsc1 and Tsc2 mice (male and female, pooled) both have impaired hippocampal learning and memory (Goorden et al., 2007; Ehninger et al., 2008); interestingly, loss of Tsc1 from Purkinje cells alone in male mice mimics many phenotypes of the disorder (Tsai et al., 2012).”
Zucco, A. J., Pozzo, V. D., Afinogenova, A., Hart, R. P., Devinsky, O., & D’Arcangelo, G. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.08.004 · Cited by 51
Resolving the Synaptic versus Developmental Dichotomy of Autism Risk Genes
Heavner, W. E., & Smith, S. E. P. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.01.009 · Cited by 53
Lieberman, O. J., Cartocci, V., Pigulevskiy, I., Molinari, M., Carbonell, J., Broseta, M. B., Post, M. R., Sulzer, D., Borgkvist, A., & Santini, E. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00070 · Cited by 50
“…ASD diagnosis [Diagnostic and Statistical Manual of Mental Disorders [DSM-5 R©], 2013] and are present in genetic models of ASD (Kwon et al., 2006; Ehninger et al., 2008; Zhou et al., 2009; Tsai et al., 2012, 2018; Gkogkas et al., 2013; Santini et al., 2013; Huynh et al., 2015) and VPA-treated…”
BackgroundMethodOberman, L. M. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.729819 · Cited by 50
“Similarly, in TSC2 mouse models, mTOR antagonists rescued not only the synaptic plasticity, but also spatial learning and contextual discrimination deficits [35].”
BackgroundmTOR inhibitors as a new therapeutic option for epilepsy
Curatolo, P., & Moavero, R. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.49 · Cited by 51
Structural and molecular correlates of cognitive aging in the rat
Mota, C., Taipa, R. J. F., das Neves, S. P., Monteiro-Martins, S., Monteiro, S., Palha, J. A., Sousa, N., Sousa, J. C., & Cerqueira, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-39645-w · Cited by 51
Potter, W. B., Basu, T., O’Riordan, K. J., Kirchner, A., Rutecki, P. A., Bürger, C., & Roopra, A. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001627 · Cited by 50
“TSC2+/2 Mice Display a Perseverative Behavioral Phenotype That Can Be Corrected by MPEP In a previous report, Ehninger et al. (2008) analyzed cognitive and stress-related behaviors associated with tuberous sclerosis in TSC2+/2 mice.”
Treatment of Pediatric Low-Grade Gliomas
Sait, S. F., Giantini-Larsen, A., Tringale, K. R., Souweidane, M. M., & Karajannis, M. A. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01257-3 · Cited by 54
Effects of rapamycin and TOR on aging and memory: implications for Alzheimer’s disease
Santos, R. X., Correia, S. C., Cardoso, S., Carvalho, C., Santos, M. S., & Moreira, P. I. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07262.x · Cited by 46
“Rapamycin treatment rescued not only synaptic plasticity but also behavioral deficits (Ehninger et al. 2008).”
BackgroundInfluentialConvergent evidence for mGluR5 in synaptic and neuroinflammatory pathways implicated in ASD
Zantomio, D., Chana, G., Laskaris, L., Testa, R., Everall, I., Pantelis, C., & Skafidas, E. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.02.006 · Cited by 55
Cambiaghi, M., Cursi, M., Magri, L., Castoldi, V., Comı, G., Minicucci, F., Galli, R., & Leocani, L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.003 · Cited by 47
Adult reversal of cognitive phenotypes in neurodevelopmental disorders
Silva, A. J., & Ehninger, D. (2009) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-009-9018-7 · Cited by 50
“Even though mice heterozygous for TSC genes do not show either cortical tubers or spontaneous seizures [34, 35], homozygous TSC mutants have a more severe phenotype that includes seizures, neurological impairments and lethality.”
BackgroundResultInfluentialSelf-citationGipson, T., & Johnston, M. V. (2012) · Neural Plasticity · doi:10.1155/2012/486402 · Cited by 47
Woodrum, C., Nobil, A. M., & Dabora, S. L. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-14 · Cited by 50
“dence that TSC tumor preclinical models are relevant to TSC brain manifestations as several mouse models with TSC related brain abnormalities (seizures or cognitive deficits) also had a reduction of disease severity with rapamycin treatment [ 67-69 ].”
BackgroundTuberous sclerosis complex: From molecular biology to novel therapeutic approaches
Switon, K., Kotulska, K., Janusz, A., Zmorzyńska, J., & Jaworski, J. (2016) · IUBMB Life · doi:10.1002/iub.1579 · Cited by 51
Schubert‐Bast, S., Rosenow, F., Klein, K. M., Reif, P. S., Kieslich, M., & Strzelczyk, A. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.05.039 · Cited by 46
Schneider, M., de Vries, P. J., Schönig, K., Rößner, V., & Waltereit, R. (2017) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-016-0703-8 · Cited by 41
“Mouse models of TSC have been shown to have cognitive deficits that were reversed on mTOR inhibitors [4]; similarly Tsc1+/− and Tsc2+/− mice have been shown to have ASD-like social behaviour deficits that were also reversed on mTOR inhibitors [5, 6].”
BackgroundLong, J., Li, H., Liu, Y., Liao, X., Tang, Z., Han, K., Chen, J., & Zhang, H. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1364858 · Cited by 49
Prenatal Rapamycin Results in Early and Late Behavioral Abnormalities in Wildtype C57Bl/6 Mice
Tsai, P. T., Greene-Colozzi, E. A., Goto, J., Anderl, S., Kwiatkowski, D. J., & Şahin, M. (2012) · Behavior Genetics · doi:10.1007/s10519-012-9571-9 · Cited by 48
“In addition, both Tsc1 and Tsc2 mice demonstrate deficient hippocampal dependent learning and social impairment (Ehninger et al. 2008; Goorden et al. 2007).”
InfluentialSelf-citationOhashi, R., Takao, K., Miyakawa, T., & Shiina, N. (2016) · Scientific Reports · doi:10.1038/srep20775 · Cited by 47
Negative Effects of Chronic Rapamycin Treatment on Behavior in a Mouse Model of Fragile X Syndrome
Saré, R. M., Song, A., Loutaev, I., Cook, A., Maita, I., Lemons, A., Sheeler, C., & Smith, C. B. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00452 · Cited by 43
“In mice, acute rapamycin impaired performance on the Morris water maze (Ehninger et al., 2008), subacute rapamycin impaired performance on object place recognition (Zhou et al., 2013), and chronic rapamycin increased anxiety-like behavior (Russo et al., 2016) and resulted in deficits in social…”
BackgroundVanclooster, S., Bissell, S., van Eeghen, A. M., Chambers, N. J., Waele, L. D., Byars, A. W., Capal, J. K., Cukier, S., Davis, P. E., Flinn, J., et al. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09423-3 · Cited by 46
“Very few animal studies explored dysregulated behaviour (3/30; 10%; [48, 94, 154]), eat/sleep (3/30; 10%; [48, 154, 155]) or the overactive/impulsive clusters (2/30; 7%; [154, 156]).”
BackgroundChapter 8 Translational Regulatory Mechanisms in Synaptic Plasticity and Memory Storage
Costa‐Mattioli, M., Sonenberg, N., & Richter, J. D. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)90008-4 · Cited by 53
“In addition, PTEN hamartoma syndrome, which is caused by the loss of function in PTEN, an upstream negative regulator of mTOR, has been linked to ASD pathogenesis.(47,48) Neurofibromatosis type I, which is generated by mutations in neurofibromin (NF1), a Ras GAP, results in upregulation of Ras/Erk which in turns leads…”
BackgroundPeters, J. M., Taquet, M., Prohl, A. K., Scherrer, B., van Eeghen, A. M., Prabhu, S. P., Şahin, M., & Warfield, S. K. (2013) · Future Neurology · doi:10.2217/fnl.13.37 · Cited by 48
“In mouse models, mTOR-i improve learning and prevent autistic features [98,121].”
BackgroundInfluence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism
Silverman, J. L., Babineau, B. A., Oliver, C. F., Karras, M. N., & Crawley, J. N. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.07.042 · Cited by 46
“…to evaluate genetic reversal and pharmacological rescue in mouse models of neurodevelopmental disorders (Cobb et al., 2010; Dolen et al., 2007; Ehninger et al., 2008a, 2008b; Guy et al., 2007; Hayashi et al., 2007; Meikle et al., 2008; Ogier et al., 2007; Penagarikano et al., 2011; Silverman…”
Birca, A., Mercier, C., & Major, P. (2010) · Journal of Neurosurgery Pediatrics · doi:10.3171/2010.7.peds10221 · Cited by 41
Astrocytes conspire with neurons during progression of neurological disease
McGann, J. C., Lioy, D. T., & Mandel, G. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.03.009 · Cited by 41
Yui, K., Sato, A., & Imataka, G. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150324122930 · Cited by 40
“Mice show far more severer phenotypes, such as epilepsy, brain enlargement and early mortality, when Tsc1 or Tsc2 is eliminated in astrocytes [49] and in neurons of the forebrain [46].”
BackgroundInfluentialAgeing, Neuronal Connectivity and Brain Disorders: An Unsolved Ripple Effect
Bano, D., Agostini, M., Melino, G., & Nicotera, P. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8164-6 · Cited by 45
“Pharmacologically, inhibition of TOR by rapamycin extends the life span of rodents [10] and can moreover abolish amyloidosisassociated cognitive decline [11] or other genetic neurodegenerative disorders [12].”
BackgroundWang, S., Zhou, S., Min, F.-Y., Ma, J.-J., Shi, X., Bereczki, E., & Wu, J. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9528-1 · Cited by 41
“Also, in several disease models, hyperactive hippocampal mTOR signaling are demonstrated to have detrimental effects on cognitive deficits (Caccamo et al. 2010; Ehninger et al. 2008).”
BackgroundDysregulation of mTOR Signaling in Neuropsychiatric Disorders: Therapeutic Implications
Sawicka, K., & Zukin, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.210 · Cited by 41
Genetic animal models of malformations of cortical development and epilepsy
Wong, M., & Roper, S. N. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.04.007 · Cited by 42
“Similarly, adult mice with heterozygyous Tsc1 or Tsc2 mutations have not been reported to have pathological brain abnormalities or seizures, although they do have learning deficits (Ehninger et al., 2008; Goorden et al., 2007).”
BackgroundHwang, S., Lee, J., Yang, J.-E., Lim, C., Lee, J., Lee, Y., Lee, K., & Kaang, B. (2016) · Molecular Brain · doi:10.1186/s13041-016-0222-6 · Cited by 40
“For example, Ehninger and colleagues showed that rapamycin treatment reversed the deficits in learning and in hippocampal synaptic plasticity in Tsc2 mice [18].”
BackgroundBrown, E., Lautz, J. D., Davis, T. R., Gniffke, E. P., VanSchoiack, A., Neier, S. C., Tashbook, N., Nicolini, C., Fahnestock, M. L., Schrum, A. G., et al. (2018) · Molecular Autism · doi:10.1186/s13229-018-0229-1 · Cited by 47
“Taken together, these data indicate reduced NMDAR2B and SynGAP expression, abnormal scaffolding of mGluR5 to Sap97, and abnormal FYN signaling, which could contribute to the altered LTP phenotype reported in the hippocampus of TSC mice [37].”
BackgroundHypothesis‐driven investigations of diverse pharmacological targets in two mouse models of autism
Rhine, M. A., Parrott, J. M., Schultz, M. N., Kazdoba, T. M., & Crawley, J. N. (2019) · Autism Research · doi:10.1002/aur.2066 · Cited by 47
“Mice were treated with vehicle or 10 mg/kg, injected intraperitoneally in a volume of 10 ml/kg. Doses were chosen from previous publications on behavioral actions of rapamycin in mice [Ehninger et al., 2008; Tsai et al., 2012; Sato et al., 2012; Cambiaghi et al., 2013; Burket et al., 2014].”
MethodDickinson, A. H., Varcin, K. J., Şahin, M., Nelson, C. A., & Jeste, S. (2019) · Autism Research · doi:10.1002/aur.2193 · Cited by 42
“, 2010], synaptic plasticity and function [Ehninger et al., 2008; Zeng et al., 2007], excitation-inhibition balance [Bateup et al.”
BackgroundDelaney, S. P., Julian, L. M., & Stanford, W. L. (2014) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2014.00069 · Cited by 45
“For instance, the majority of TSC patients have germline mutations, and thus all cell lineages, including both neural and neural crest progenitors, are vulnerable to the acquisition of second-hit mutations.”
BackgroundRaptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex
Karalis, V., Caval-Holme, F., & Bateup, H. S. (2022) · Nature Communications · doi:10.1038/s41467-022-31961-6 · Cited by 40
Liaci, C., Camera, M., Caslini, G., Rando, S., Contino, S., Romano, V., & Merlo, G. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116167 · Cited by 42
“Tsc2+/− and Tsc1 homozygous mutant mice (a model of tuberous sclerosis), were treated with rapamycin, rescuing spatial learning and context discrimination deficits together with neurological findings [395,396].”
BackgroundZeng, L., Rensing, N. R., & Wong, M. (2009) · Molecular and Cellular Pharmacology · doi:10.4255/mcpharmacol.09.16 · Cited by 42
“Similarly, in mouse models of TSC with abnormal neurological phenotypes, mTOR inhibitors can reverse a number of molecular, histological, and behavioral abnormalities that may relate to epileptogenesis, including megenecephaly, neuronal hypertrophy, and astrogliosis (24-27).”
BackgroundDiagnosis and Management of Autism Spectrum Disorder in the Era of Genomics
Baker, E. J., & Jeste, S. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.03.003 · Cited by 44
“These studies have revealed that mTOR inhibitors can reverse the cognitive and social impairments found in adult mouse models after surprisingly short courses of treatment.(36,37) In turn, these promising findings have inspired the investigation of mTOR inhibitors, such as rapamycin, in patients with TSC.”
BackgroundIs autism driven by epilepsy in infants with Tuberous Sclerosis Complex?
Moavero, R., Kotulska, K., Lagae, L. G., Benvenuto, A., Gialloreti, L. E., Weschke, B., Riney, K., Feucht, M., Kršek, P., Nabbout, R., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51128 · Cited by 42
Self-citationEffects of Mutations in TSC Genes on Neurodevelopment and Synaptic Transmission
Bassetti, D., Luhmann, H. J., & Kirischuk, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147273 · Cited by 45
“In the hippocampus, no changes in evoked field potential amplitude at Schaffer collateralsCA1 synapses was observed in both Tsc2+/− rats [79] and mice [41,80].”
BackgroundFMRP S499 Is Phosphorylated Independent of mTORC1-S6K1 Activity
Bartley, C. M., O’Keefe, R. A., & Bordey, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096956 · Cited by 42
Huynh, T. N., Santini, E., & Klann, E. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0878-14.2014 · Cited by 39
“The following antibodies were used: phospho-Ser240/244 –S6 ribosomal protein, phospho-ERK1/2, S6 ribosomal protein, and ERK1/2 (Cell Signaling Technology).”
BackgroundInfluentialUsing genetic findings in autism for the development of new pharmaceutical compounds
Vorstman, J. A. S., Spooren, W. P. J. M., Persico, A. M., Collier, D. A., Aigner, S., Jagasia, R., Glennon, J. C., & Buitelaar, J. K. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3334-z · Cited by 45
McClorry, S., Zavaleta, N., Llanos, A., Casapía, M., Lönnerdal, B. L., & Slupsky, C. M. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy249 · Cited by 48
Interneuron Dysfunction in Syndromic Autism: Recent Advances
Takano, T. (2015) · Developmental Neuroscience · doi:10.1159/000434638 · Cited by 42
Dayas, C. V., Smith, D. W., & Dunkley, P. R. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00013 · Cited by 224
Hoeffer, C. A., Santini, E., Ma, T., Arnold, E. C., Whelan, A. M., Wong, H., Pierre, P., Pelletier, J., & Klann, E. (2013) · Journal of Neurophysiology · doi:10.1152/jn.00342.2012 · Cited by 37
“In several instances, synaptic plasticity and cognitive deficits in animal models of human disorders have been reversed using inhibitors of protein synthesis (Ehninger et al. 2008; Zhou et al. 2009).”
BackgroundMolecular mechanisms controlling protein synthesis in memory reconsolidation
Roesler, R. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.04.015 · Cited by 41
The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial
Amin, S., Mallick, A. A., Edwards, H. B., Cortina‐Borja, M., Laugharne, M. J., Likeman, M. J., & O'Callaghan, F. J. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100715 · Cited by 40
“Rapamycin has been shown to reverse learning deficits and improve epilepsy in mouse models of TSC [10].”
BackgroundBlair, J. D., & Bateup, H. S. (2019) · Developmental Dynamics · doi:10.1002/dvdy.60 · Cited by 39
Research models of neurodevelopmental disorders: The right model in the right place
Damianidou, E., Mouratidou, L., & Kyrousi, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1031075 · Cited by 46
“Deficits in learning, memory and social behavior in Tsc1+/− and Tsc2+/− mice emerged in the absence of neuropathology and seizures (Goorden et al., 2007; Ehninger et al., 2008), indicating that animal models do not recapitulate faithfully the human phenotype.”
BackgroundWang, P., Cao, J., Liu, N., Ma, L., Zhou, X., Zhang, H., & Wang, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153708 · Cited by 36
“Moreover, it has also been demonstrated to partially influence synaptic plasticity and memory [24, 25] through regulating the synthesis of certain proteinassociated with reshaping of the synapse [58, 59].”
BackgroundRichard, A., Scheffer, I. E., & Wilson, S. J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.036 · Cited by 39
“model proposes that defects in translational regulation in the mTOR pathway contribute to expression of the epilepsy-ASD comorbidity through enhanced protein synthesis and consequent hyperplasticity (Ehninger et al., 2008; Huber et al., 2002; Kwon et al., 2006).”
Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment
Mizuguchi, M., Ohsawa, M., Kashii, H., & Sato, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136677 · Cited by 42
“Importantly, these deficits can be reversed by pharmacological treatment with rapamycin [17].”
BackgroundFallah, A., & Wang, S. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s51789 · Cited by 38
“Sirolimus (rapamycin) and everolimus have been shown to be effective in the treatment of upregulation in cancers, and preliminary data for its use in the TSC population are promising.(45,46) Everolimus was recently approved by the FDA in 2010 to treat SEGA in TSC following encouraging animal and human clinical data.”
Management of CNS-related Disease Manifestations in Patients With Tuberous Sclerosis Complex
Krueger, D. A. (2013) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0249-2 · Cited by 36
Fretham, S. J. B., Carlson, E. S., & Georgieff, M. (2013) · Journal of Nutrition · doi:10.3945/jn.112.168617 · Cited by 40
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.